professionalIMG

Linda Rockett

Member vCard
Boston
617.348.4888



Education

  • University of Miami (JD)
  • Tufts University (BA)

Bar Admissions

  • Massachusetts

Linda’s practice involves most aspects of corporate and transactional law and general business representation, including corporate formation and governance, venture capital, mergers and acquisitions, securities law and compliance, equity, debt and convertible debt financings, and general business counseling.

Her work carries an emphasis on public offerings, venture capital financings, and mergers and acquisitions, primarily for life sciences and technology companies. Linda also regularly advises both public and private companies at various stages of development on a variety of general corporate matters.

During law school, she was an editor of the University of Miami Business Law Review and a member of the Moot Court Board.

Before attending law school, Linda worked as a financial software consultant in London, Hong Kong, and Sydney.

Representative Matters

Public Offerings

  • Represented BG Medicine, Inc. (Nasdaq: BGMD) in its $40 million initial public offering
  • Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in over $1 billion in various equity and debt public offerings
  • Represented ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) in its $258 million follow-on public offering and other public offerings
  • Represented Synta Pharmaceuticals Corp. (Nasdaq: SNTA) in its $35 million equity line facility with Azimuth Opportunity Ltd.
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $105 million follow-on public offering and other public offerings

Mergers & Acquisitions

  • Represented Ember Corporation in its $72 million acquisition by Silicon Laboratories Inc. (SLAB)
  • Represented Myriad Genetics, Inc. (Nasdaq: MYGN) in its $80 million acquisition of Rules-Based Medicine, Inc.
  • Represented Arbinet Corporation (Nasdaq: ARBX) in its acquisition by Primus Telecommunications Group, Inc. (NYSE: PTGI)
  • Represented ION Torrent Systems Incorporated in its $725 million acquisition by Life Technologies Corporation (Nasdaq: LIFE)
  • Represented Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its $300+ million (cash and stock) acquisition of ViroChem Pharma, Inc.
  • Represented iBasis, Inc. (Nasdaq: IBAS) in it $100 million sale to Royal KPN, NV
  • Represented ClariFI, Inc. in its acquisition by Standard & Poor’s, a division of the Mc-Graw Hill Companies (NYSE: MHP) (undisclosed amount)
  • Represented Netonomy, Inc. in its $19 million acquisition by Comverse Technology, Inc. (Nasdaq: CMVT)

Venture Capital Financings

  • Represented Pulmatrix, Inc. in various preferred stock and convertible debt financings and in general corporate matters
  • Represented BG Medicine, Inc. (BGMD) in its $40 million Series D financing and in general corporate matters
  • Represented Virtify, Inc. in various preferred stock financings and in general corporate matters
  • Represented Ember Corporation in various preferred stock and convertible debt financings and in general corporate matters
  • Represented Allegro Diagnostics Corp. in various convertible debt financings and in general corporate matters

Recognitions & Awards

  • Massachusetts Super Lawyers: Rising Star – Business/Corporate (2009 – 2013)